Stephens analysts lower Braze stock price target to $41 from $51

Published 06/06/2025, 12:24
Stephens analysts lower Braze stock price target to $41 from $51

On Friday, Stephens analysts adjusted their outlook on Braze Inc (NASDAQ: NASDAQ:BRZE) by reducing the price target to $41 from the previous $51, while maintaining an Overweight rating. The decision reflects the company’s sequential deceleration in subscription revenue and lower sequential net revenue retention (NRR). According to InvestingPro data, Braze maintains a healthy balance sheet with a current ratio of 1.92 and more cash than debt, despite posting losses in the last twelve months.

Despite these challenges, the analysts noted Braze’s growth resilience, highlighted by a projected 19% increase in the 2026 guide. This growth is seen as remarkable given the market’s concerns over variability in marketing spending. The company has demonstrated strong execution with revenue growth of 22.66% and an impressive gross margin of 69.44%. InvestingPro analysis reveals 6 additional key insights about Braze’s financial health and growth prospects.

The revised price target is based on a 5.1x enterprise value to fiscal year 2 revenue, representing a 23% discount to the 6.6x post-COVID average. The analysts continue to see more pros than cons for Braze in the first quarter, justifying the maintained Overweight rating.

Braze, a customer engagement platform, has been navigating a challenging market environment, which has impacted its financial metrics. The company’s ability to sustain growth amid these conditions remains a focal point for investors.

In other recent news, Braze Inc reported fiscal first-quarter results that exceeded consensus estimates, with a 20% year-over-year revenue increase. Despite this strong performance, Oppenheimer adjusted its price target for Braze to $44 due to concerns about revenue quality, while maintaining an Outperform rating. Needham analysts reiterated a Buy rating and kept a $50 price target, highlighting a 24.3% year-over-year increase in committed recurring purchase orders. Raymond (NSE:RYMD) James also maintained an Outperform rating but lowered the price target to $43, citing potential short-term challenges despite positive results. DA Davidson maintained a Buy rating with a $40 price target, emphasizing better-than-expected profitability and the strategic acquisition of OfferFit. JPMorgan reduced its price target to $45, noting the acquisition’s impact on financial guidance, but maintained an Overweight rating. Overall, Braze’s recent acquisition and strong revenue growth have drawn positive attention from analysts, who anticipate future growth despite some short-term challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.